Dynavax's HEPLISAV(TM) Hepatitis B Vaccine Shows 100% Seroprotection Regardless Of Vaccination Schedule In Phase 2 Trial

Tue, 05 Dec 2006 02:00 PM EST

... Dynavax Technologies Corporation (Nasdaq: DVAX) announced today positive results from a Phase 2 trial comparing two different vaccination schedules of HEPLISAV, its hepatitis B virus (HBV) vaccine. The primary endpoint is comparative seroprotection after the second dose. The data was reported today in a poster at the Canadian Immunization Conference in Winnipeg, Manitoba, Canada by Dr. [click link for full article] ...